Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications, including cancer recurrence, the drugmaker said on ...

Pfizer's Phase III trial of sasanlimab with BCG in subjects with BCG-naïve, high-risk NMIBC, has met its primary endpoint.

Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

Pfizer's Bladder Cancer Therapy Meets Main Goal in Late-Stage Study (Reuters) -Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained ...

Pfizer chief oncology officer Roger Dansey said: “The initial therapy of high-risk, non-muscle invasive bladder cancer with BCG has not advanced in decades. Today’s pivotal Phase III CREST ...

(Reuters) -Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications, including cancer recurrence ...